PMC

Behavior of SE. (A) Percentage of experimental subjects that developed SE. Data are presented as the percentage of animals that exhibited SE in the different experimental groups. (B) Time to the onset of the first generalized seizure, comparison of groups: vehicle vs AMLA 500 mg/kg, AMLA 700 mg/kg, and CBZ 300 mg/kg through Kruskal-Wallis followed by Tukey’s post hoc test. (C) Time to SE induction, comparison of groups: vehicle vs AMLA 500 mg/kg, AMLA 700 mg/kg, and CBZ 300 mg/kg through Kruskal-Wallis followed by Tukey’s post hoc test. (D) Duration of the first generalized seizure: vehicle vs AMLA 500 mg/kg, AMLA 700 mg/kg, and CBZ 300 mg/kg using one-way ANOVA followed by Tukey’s post hoc test. (E) Number of stage IV and stage (F) V generalized seizures, comparison of groups: vehicle vs AMLA 500 mg/kg, AMLA 700 mg/kg, and CBZ 300 mg/kg through Kruskal-Wallis followed by Tukey’s post hoc test. Data are expressed as mean ± SEM. *P < 0.05, compared to the vehicle group.

Differently dried amla powders from fresh amla pulp

(a) Triglyceride level in amla extract and placebo group (p = 0.0003 between the groups); (b) Atherogenic index of plasma in amla extract and placebo group (p = 0.0177 between the groups); (c) Ratio of Apo B to Apo A1 at baseline and visit 5 in amla extract and placebo group (p = 0.0866 between the groups); (d) TC level at baseline and visit 5 in amla extract and placebo group (p = 0.0003 between the groups); (e) LDL-C level at baseline and visit 5 in amla extract and placebo group (p = 0.0064 between the groups); (f) CoQ10 level at baseline and visit 5 in amla extract and placebo group (p = 0.4581 between the groups)

(a) Metabolic pathways of amla: Urolithins are the major tentative metabolites of ellagitannins of amla formulation associated with different health benefits, and (b) Amla inhibits the vWF stimulated thrombin (TM) generation by the reduction in vWF secretion.